Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy

Background Patients with cancer are at increased risk of drug-drug interactions (DDI), which can increase treatment toxicity or decrease efficacy. It is especially important to thoroughly screen DDI in oncology clinical trial subjects to ensure trial subject safety and data accuracy. This study dete...

Full description

Saved in:

Bibliographic Details
Published in:	BMC cancer Vol. 21; no. 1; pp. 324 - 6
Main Authors:	Marcath, Lauren A., Finley, Colin M., Wong, Siu Fun, Hertz, Daniel L.
Format:	Journal Article
Language:	English
Published:	London BioMed Central 26.03.2021 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Acids Administration, Oral Analgesics Antacids Antimitotic agents Antineoplastic agents Antineoplastic Agents - therapeutic use Biomedical and Life Sciences Biomedicine Cancer Cancer Research Cancer therapies Chemotherapy Clinical trials Complications and side effects Contraindications Drug interactions Drug Interactions - physiology Enrollments Epidemiology Female Health Promotion and Disease Prevention Humans Inhibitor drugs Male Medicine/Public Health Neoplasms - drug therapy Oncology Oncology clinical trial drug interaction Oral cancer Oral medication Patient safety Pharmaceutical research prevention and public health Research Article Standard deviation Statistical analysis Surgical Oncology Testing Toxicity United States Oncology clinical trial drug interaction
ISSN:	1471-2407, 1471-2407
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!